WHO ICTRP trial
THETIS- Efficacy and Safety Study of Deferasirox in Patients With…
LBCTR2020011375 · Lebanon Clinical Trials Registry (LBCTR) · Not Recruiting
Key facts
| Trial ID | LBCTR2020011375 |
|---|---|
| Public title | THETIS- Efficacy and Safety Study of Deferasirox in Patients With Non-transfusion Dependent Thalassemia |
| Scientific title | An Open Label, Multi-center, Efficacy and Safety Study of Deferasirox in Iron Overloaded Patients With Non-transfusion Dependent Thalassemia |
| Primary sponsor | Novartis Pharmaceuticals |
| Registry | Lebanon Clinical Trials Registry (LBCTR) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | 4 |
| Countries | Lebanon;China;Greece;Italy;Thailand;Tunisia;Turkey |
| Conditions | Non-transfusion Dependent Thalassemia Non-transfusion Dependent Thalassemia;D56.9;Non-transfusion Dependent Thalassemia |
| Interventions | Drug: deferasirox Deferasirox dispersible tablets at strengths of 125 mg, 250 mg, and 500 mg were administered by oral daily dosing. Other Name: ICL670;ICF, Labs, drug administraion , Radiology;ICF, Labs, drug administraion , Radiology |
| Registration date | Jul 1, 2020 |
| Target size | 20 |
| Secondary IDs | NCT01709838 |
| Registry page | lbctr.moph.gov.lb |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: